The bad news clearly outweighed the good from Pfizer Inc.’s Phase IIb trial of its twice-daily, oral GLP-1 agonist danuglipron for obesity on 1 December, as the pharma said it would not advance the drug into Phase III in its current formulation. Pfizer still is holding out hope for a once-daily formulation it is developing, however, pointing to a pharmacokinetic data readout it expects during the first half of 2024.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?